Healthcare
Live Price
Offline$4.42
+4.74% today
1Y Change
+113.85%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Whitehawk Therapeutics Inc (WHWK) is a Healthcare stock with a market cap of $210.00M and listed on NASDAQ. The stock last traded around $4.42 and up 113.8% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of -72.5%, EPS growth of +86.0%, a dividend yield of 0.0%. What stands out right now is revenue -72.5%, EPS +86.0%, free cash flow -60.1% with operating margin -1601.1% and ROIC -83.9%. Valuation already assumes a fairly strong business story at price/sales 28.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines WHWK price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
WHWK
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
WHWK Max Drawdown
-25.19%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for WHWK and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.1M
-92.6% YoY
FY Net Income
-$110.1M
-81.9% YoY
Free Cash Flow
-$22.5M
+55.1% YoY
Revenue Growth
-72.5%
EPS Growth
+86.0%
Gross Margin
89.3%
Net Margin
-288.3%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 7M | 26M | 24M | 15M | 1M |
| Gross Profit | 6M | -28M | -27M | -19M | -19M |
| Operating Income | -114M | -67M | -72M | -63M | -111M |
| EBITDA | -114M | -65M | -72M | -59M | -37M |
| Net Income | -21M | -64M | -66M | -61M | -110M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 38M | 29M | 63M | 39M | 149M |
| Total Assets | 151M | 70M | 132M | 184M | 158M |
| Total Liabilities | 15M | 18M | 27M | 26M | 22M |
| Shareholder Equity | 136M | 52M | 105M | 158M | 136M |
| Total Debt | 0 | 833K | 1M | 2M | 605K |
| Net Debt | -38M | -28M | -62M | -37M | -148M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
22M
+54.8% YoY
Capital Expenditures
46K
+89.6% YoY
Free Cash Flow
22M
+55.1% YoY
Key ratios
Gross Margin
89.3%
Operating Margin
-1601.1%
Net Margin
-288.3%
ROE
-12.0%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.